1. Home
  2. UPBD vs MESO Comparison

UPBD vs MESO Comparison

Compare UPBD & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UPBD
  • MESO
  • Stock Information
  • Founded
  • UPBD 1986
  • MESO 2004
  • Country
  • UPBD United States
  • MESO Australia
  • Employees
  • UPBD N/A
  • MESO N/A
  • Industry
  • UPBD Diversified Commercial Services
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • UPBD Consumer Discretionary
  • MESO Health Care
  • Exchange
  • UPBD Nasdaq
  • MESO Nasdaq
  • Market Cap
  • UPBD 1.6B
  • MESO 1.7B
  • IPO Year
  • UPBD 1995
  • MESO N/A
  • Fundamental
  • Price
  • UPBD $24.20
  • MESO $11.90
  • Analyst Decision
  • UPBD Buy
  • MESO Buy
  • Analyst Count
  • UPBD 4
  • MESO 4
  • Target Price
  • UPBD $37.00
  • MESO $18.00
  • AVG Volume (30 Days)
  • UPBD 587.4K
  • MESO 302.9K
  • Earning Date
  • UPBD 05-01-2025
  • MESO 02-26-2025
  • Dividend Yield
  • UPBD 6.45%
  • MESO N/A
  • EPS Growth
  • UPBD N/A
  • MESO N/A
  • EPS
  • UPBD 2.21
  • MESO N/A
  • Revenue
  • UPBD $4,320,564,000.00
  • MESO $5,670,000.00
  • Revenue This Year
  • UPBD $8.46
  • MESO $228.57
  • Revenue Next Year
  • UPBD $6.87
  • MESO $356.77
  • P/E Ratio
  • UPBD $10.95
  • MESO N/A
  • Revenue Growth
  • UPBD 8.22
  • MESO N/A
  • 52 Week Low
  • UPBD $23.35
  • MESO $4.60
  • 52 Week High
  • UPBD $38.72
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • UPBD 40.35
  • MESO 31.48
  • Support Level
  • UPBD $23.36
  • MESO $13.60
  • Resistance Level
  • UPBD $25.60
  • MESO $14.45
  • Average True Range (ATR)
  • UPBD 0.69
  • MESO 0.48
  • MACD
  • UPBD 0.09
  • MESO -0.03
  • Stochastic Oscillator
  • UPBD 37.78
  • MESO 3.77

About UPBD Upbound Group Inc.

Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has four operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions across e-commerce, digital, and mobile channels, Mexico segment offers lease-to-own stores in Mexico. The franchising segment offers the sale of rental merchandise to its franchisees. The company derives a majority of its revenue from the Acima segment.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: